FABRAZYME
Drug
GENZYME CORPORATION
Total Payments
$11.7M
Transactions
11,454
Doctors
5,062
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.6M | 2,419 | 1,369 |
| 2023 | $1.7M | 2,450 | 1,462 |
| 2022 | $932,500 | 1,695 | 1,176 |
| 2021 | $590,250 | 712 | 548 |
| 2020 | $856,444 | 380 | 211 |
| 2019 | $1.1M | 1,147 | 482 |
| 2018 | $2.2M | 1,487 | 663 |
| 2017 | $1.7M | 1,164 | 531 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.8M | 589 | 58.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.9M | 887 | 24.7% |
| Consulting Fee | $868,100 | 278 | 7.4% |
| Travel and Lodging | $675,259 | 1,602 | 5.8% |
| Food and Beverage | $367,311 | 8,062 | 3.1% |
| Space rental or facility fees (teaching hospital only) | $63,739 | 35 | 0.5% |
| Gift | $30,338 | 1 | 0.3% |
Payments by Type
Research
$6.8M
589 transactions
General
$4.9M
10,865 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Fabry Disease Registry Protocol | SANOFI US SERVICES INC. | $1.6M | 0 |
| KINDRED - Kidney Information Network for Disease Research and Education | GENZYME CORPORATION | $783,518 | 0 |
| Localization of Globotriaosylceramide (GL3) Inclusions in Fabry Podocytes | GENZYME CORPORATION | $571,414 | 0 |
| Characterization and analysis of pathophysiology of the gastrointestinal complications of Fabry disease. | GENZYME CORPORATION | $447,662 | 0 |
| Renal Biopsy Studies in Fabry Disease Patients with Late-onset/cardiac Phenotypes (LO/C-P) | GENZYME CORPORATION | $399,923 | 0 |
| Pre-Clinical Detection of White Matter Changes in Fabry Disease with Quantitative MRI | GENZYME CORPORATION | $372,383 | 0 |
| A controlled study of switching high risk relapsing multiple sclerosis patients treated with natalizumab to teriflunomide: Is this safe and effective? | GENZYME CORPORATION | $284,248 | 0 |
| The Prevalence, Morphology, Clinical Course and Management of Patients with Anderson-Fabry Disease Identified Among a Large Adult Population of Patients with Hypertriphic Cardiomyopathy | GENZYME CORPORATION | $230,700 | 0 |
| Enzyme Replacement Therapy and Podocyte Function | GENZYME CORPORATION | $227,657 | 0 |
| A Study to Investigate Safety and Tolerability of Higher Infusion Rate to shORten the duraTion of FabrazymE Infusion | SANOFI US SERVICES INC. | $217,579 | 0 |
| Establishing an in-vitro Model of Fabry Podocytopathy | GENZYME CORPORATION | $185,309 | 0 |
| Impact of enhancers on expression of GLA, HNRNPH2 and RPL36A genes in Fabry disease male and female cell lines. | GENZYME CORPORATION | $178,790 | 0 |
| Q1 2018 Fabry LSD Registry | GENZYME CORPORATION | $137,542 | 0 |
| A Prospective, Multicenter Study Of Fabry Disease Clinical and Biochemical Findings in Young Pediatric Patients (The MOPPET Study) | GENZYME CORPORATION | $120,671 | 0 |
| Comparative Proteomics and Lipidomics of Exosomes Isolated from Serum and Urine in Fabry Disease | GENZYME CORPORATION | $116,741 | 0 |
| The Fabry Pain Inventory: Validation of a New Clinical Tool to Comprehensively Capture the Fabry Pain Experience | GENZYME CORPORATION | $115,108 | 0 |
| Fabry Disease Registry | GENZYME CORPORATION | $106,035 | 5 |
| Determinants of renal structural responses to enzyme replacement therapy in Fabry disease | GENZYME CORPORATION | $92,655 | 0 |
| Novel molecular approaches for diagnosis and therapy of Fabry disease patients as supplemental to current diagnosis and enzyme replacement therapy by ?Fabrazyme?. | GENZYME CORPORATION | $89,968 | 0 |
| Fabry Registry | GENZYME CORPORATION | $89,519 | 0 |
Top Doctors Receiving Payments for FABRAZYME
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Rochester, NY | $6.9M | 631 |
| , MD | Medical Genetics, Ph.D. Medical Genetics | Valhalla, NY | $467,634 | 454 |
| , PH.D., M.D | Clinical Genetics (M.D.) | New York, NY | $378,321 | 83 |
| , MD | Nephrology | Los Angeles, CA | $293,314 | 301 |
| , M.D | Nephrology | Dallas, TX | $263,713 | 244 |
| , M.D | Clinical Genetics (M.D.) | Cincinnati, OH | $214,488 | 177 |
| , O.D | Low Vision Rehabilitation | Schenectady, NY | $213,229 | 186 |
| , MD, PHD | Interventional Cardiology | Washington, DC | $201,404 | 97 |
| , M.D | Internal Medicine | Billings, MT | $168,406 | 101 |
| , M.D | Nephrology | Norfolk, VA | $162,683 | 185 |
| , M.D | Clinical Genetics (M.D.) | Galveston, TX | $156,079 | 161 |
| , M.D | Pediatric Cardiology | Cincinnati, OH | $151,065 | 140 |
| , MD | Pediatrics | Minneapolis, MN | $109,104 | 111 |
| , RN, NP | Nurse Practitioner | Detroit, MI | $90,401 | 128 |
| , MD | Clinical Genetics (M.D.) | Greenville, SC | $84,668 | 84 |
| , MD | Internal Medicine | Westlake, OH | $75,464 | 61 |
| , MD | Cardiovascular Disease | Oakbrook Terrace, IL | $74,681 | 46 |
| , MD | Pediatric Nephrology | Corpus Christi, TX | $72,791 | 69 |
| , MD | Nephrology | Birmingham, AL | $66,302 | 49 |
| , M.D | Student in an Organized Health Care Education/Training Program | Chicago, IL | $64,340 | 44 |
| , MD | Pediatrics | Long Beach, CA | $64,113 | 50 |
| , MD | Anatomic Pathology | Seattle, WA | $63,752 | 43 |
| , MD | Nephrology | Saginaw, MI | $56,091 | 52 |
| , M.D | Nephrology | Los Angeles, CA | $55,615 | 51 |
| , M.D | Pediatrics | Fairfax, VA | $50,675 | 54 |
Ad
Manufacturing Companies
- GENZYME CORPORATION $9.6M
- SANOFI US SERVICES INC. $1.8M
- SANOFI-AVENTIS U.S. LLC $219,980
- Genzyme Corporation $101,588
Product Information
- Type Drug
- Total Payments $11.7M
- Total Doctors 5,062
- Transactions 11,454
About FABRAZYME
FABRAZYME is a drug associated with $11.7M in payments to 5,062 healthcare providers, recorded across 11,454 transactions in the CMS Open Payments database. The primary manufacturer is GENZYME CORPORATION.
Payment data is available from 2017 to 2024. In 2024, $2.6M was paid across 2,419 transactions to 1,369 doctors.
The most common payment nature for FABRAZYME is "Unspecified" ($6.8M, 58.1% of total).
FABRAZYME is associated with 20 research studies, including "Fabry Disease Registry Protocol" ($1.6M).